The Pharmacogenomics by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pharmacogenomics Market:
https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report
According to The Business Research Company’s Pharmacogenomics, The pharmacogenomics market size has grown rapidly in recent years. It will grow from $8.14 billion in 2023 to $9.04 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to strong economic growth in emerging markets, the increasing focus on personalized medicine, the rising advanced healthcare infrastructure and increased healthcare expenditure.
The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $13.48 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to the increasing aging population, the increasing chronic diseases, the rising population and the increasing demand for cancer treatment. Major trends in the forecast period include launch of genome editing solution for deeper analysis of advanced therapies, focus on integration of artificial intelligence (ai) in genomics to analyze genetic data, growing advancements in metagenomics, strategic partnerships and collaborations among market players, introduction of three-dimensional (3d) genomics to study influences on gene expression and function, new product innovations with focus on infectious diseases and gene editing and development of psychotropic pharmacogenomics test for informed decisions.
The rising demand for precision medicine is driving the demand for the pharmacogenomics market. Precision medicine is a medical model that proposes healthcare customization, with medical decisions, treatments, practices, or products tailored to a subset of patients rather than a one-drug-fits-all-all model. There is a rising demand for precision medicine as it is the most advanced in oncology, having wider, exciting applications beyond oncology and late-stage diseases such as rare and genetic diseases. The main aim of precision medicine is to integrate genetic and environmental information about particular diseases and/or their responses to particular treatments. For instance, according to the article published on Linchpinseo in March 2022, the increasing demand for precision medicine investment from leading pharmaceutical companies is experiencing a 1/3 increase in the next five years. Furthermore, in the USA, 30 million people with type 2 diabetes get diagnosed and treated where precision medicine provides individualized treatment and will re-calibrate current treatment practices. Hence, the increasing demand for precision medicine will drive the pharmacogenomics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp
The pharmacogenomics market covered in this report is segmented –
1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies
2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications
3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users
Technological advancement is a key trend gaining the popularity in pharmacogenomics market. Medicine manufacturers are focusing on various approaches to pharmacogenomics analysis to provide cost-effective solutions for screening known polymorphisms and the discovery of novel variants. For instance, in May 2021, Integrated Prescription Management (IPM), a USA-based pharmacy benefits management (PBM) company, and Myriad Genetics Inc., a genetic testing and precision medicine, launched GeneSight test, a pharmacogenomics testing for patients suffering from depression or anxiety.
The pharmacogenomics market report table of contents includes:
1. Executive Summary
2. Pharmacogenomics Market Characteristics
3. Pharmacogenomics Market Trends And Strategies
4.Pharmacogenomics Market analysis
5.Pharmacogenomics Market Size And Growth
6. Pharmacogenomics Segmentation
7. Pharmacogenomics Regional And Country Analysis
.
.
.
27. Pharmacogenomics Competitive Landscape And Company Profiles
28. Pharmacogenomics Key Mergers And Acquisitions
29. Pharmacogenomics Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Illumina Inc.
- Eurofins Scientific
- Myriad Genetics Inc.
- PerkinElmer Inc.
- Centogene N.V
- Invitae Corporation
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
